BLU Share Price

Open 0.25 Change Price %
High 0.26 1 Day 0.00 0.00
Low 0.24 1 Week 0.02 8.33
Close 0.26 1 Month 0.00 0.00
Volume 153166 1 Year -0.61 -70.11
52 Week High 2.99
52 Week Low 0.20
BLU Important Levels
Resistance 2 0.28
Resistance 1 0.27
Pivot 0.25
Support 1 0.25
Support 2 0.24
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
BTO 3.19 -5.62%
BTO 3.19 -5.62%
PLI 2.00 4.71%
PLI 2.00 4.71%
More..
TSE Canada Top Gainers Stocks
TVI 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
DA-A 0.22 22.22%
INQ 4.08 21.79%
INQ 4.08 21.79%
CTU-A 0.25 19.05%
MM 0.07 16.67%
MM 0.07 16.67%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
LRT-UN 0.07 -22.22%
TLB 0.60 -16.67%
TLB 0.60 -16.67%
RKN 1.62 -12.43%
RKN 1.62 -12.43%
PWC 0.08 -11.11%
PWC 0.08 -11.11%
ORA 0.16 -11.11%
ORA 0.16 -11.11%
More..

BELLUS Health, Inc. (TSE: BLU)

BLU Technical Analysis 2
As on 9th Dec 2016 BLU Share Price closed @ 0.26 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.94 & Buy for SHORT-TERM with Stoploss of 0.26 we also expect STOCK to react on Following IMPORTANT LEVELS.
BLU Target for December
1st Target up-side 0.26
2nd Target up-side 0.28
3rd Target up-side 0.31
1st Target down-side 0.18
2nd Target down-side 0.16
3rd Target down-side 0.13
BLU Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.bellushealth.com
BLU Address
BLU
275 Armand-Frappier Boulevard
Laval, QC H7V 4A7
Canada
Phone: 450-680-4500
Fax: 450-680-4501
Interactive Technical Analysis Chart BELLUS Health, Inc. ( BLU TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on BELLUS Health, Inc.
BLU Business Profile
BELLUS Health Inc., together with its subsidiaries, focuses on the research and development of pharmaceutical drug candidates. The company’s lead program is KIACTA, which is in Phase III clinical trial for the treatment of AA amyloidosis. Its clinical stage drug candidate is Shigamab, a monoclonal antibody therapy for the treatment of hemolytic uremic syndrome related to shiga toxin-producing E. coli bacterial infections. The company also has an agreement with AmorChem Holdings Inc. to develop drug candidates for the treatment of AL amyloidosis. It has a strategic partnership with Auven Therapeutics for the development of KIACTA and Pharmascience. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.